Nurullah İlhan,MD· @drnurullahilhan · X·· 8 hours agoScore70
Body
INTerpath-001: personalized mRNA therapy meets its primary RFS endpoint in resected stage IIB–IV melanoma.
Intismeran + pembrolizumab vs placebo + pembrolizumab:
24-month RFS: 82.2% vs 70.0%
HR 0.58; P<0.001
DMFS also improved.
#INTerpath001 #ESMO2026 #Melanoma
5 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Nurullah İlhan,MD · x.com